Biggest Drug Patent Cliffs
Loss of exclusivity (LOE) marks when a drug's patents and FDA-granted exclusivity lapse, allowing generic or biosimilar competition and often sharply eroding the originator's revenue. This ranking lists the nearest upcoming patent cliffs first, sourced from the FDA Orange Book.
Top 3 · updated Jul 2, 2026.
- 1Patent/Exclusivity Expiry: OPILLPERRIGO Co plc (PRGO)Jul 13, 2026Patent Expiry
- 2Patent/Exclusivity Expiry: VIBATIVCUMBERLAND PHARMACEUTICALS INC (CPIX)Jan 1, 2027Patent Expiry
- 3Patent/Exclusivity Expiry: OXTELLAR XRSUPERNUS PHARMACEUTICALS, INC. (SUPN)Apr 13, 2027Patent Expiry
Ranked by soonest date. Only dates confirmed in a primary source (SEC filing, FDA source, or company disclosure) are shown; speculative far-future dates are excluded.
Frequently asked questions
What is loss of exclusivity (LOE)?
LOE is the point at which a drug's patents and FDA-granted exclusivities expire, permitting generic or biosimilar competitors to enter — often causing steep declines in the originator's revenue.
Where do patent expiration dates come from?
They are sourced from the FDA Orange Book, which lists the patents and exclusivity periods for each approved drug. BioSniper surfaces the latest-expiring protection per drug as the approximate generic-entry threshold.
Why does the patent cliff matter to investors?
A patent cliff can wipe out a large share of a marketed drug's sales within months of generic entry, making LOE timing a material catalyst for companies dependent on a few commercial products.